Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus sorafenib for advanced hepatocellular carcinoma: randomized phase II trial

BACKGROUND: Sorafenib (Sor) is acknowledged as a standard therapy for advanced hepatocellular carcinoma (HCC). This trial was conducted to evaluate the effect of addition of hepatic arterial infusion chemotherapy with cisplatin (SorCDDP) to Sor for the treatment of advanced HCC. PATIENTS AND METHODS...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Ann Oncol
Autori principali: Ikeda, M., Shimizu, S., Sato, T., Morimoto, M., Kojima, Y., Inaba, Y., Hagihara, A., Kudo, M., Nakamori, S., Kaneko, S., Sugimoto, R., Tahara, T., Ohmura, T., Yasui, K., Sato, K., Ishii, H., Furuse, J., Okusaka, T.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Oxford University Press 2016
Soggetti:
Original Articles
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5091321/
https://ncbi.nlm.nih.gov/pubmed/27573564
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdw323
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi